Amylyx clears Phase 3 avexitide trial as 55% efficacy advances NDA

The market was already looking for a Q3 readout and had a favorable prior-data setup. Amylyx had guided to LUCIDITY topline results in the third quarter of 2026, while earlier studies had shown statistically significant reductions in hypoglycemic events. That makes the positive direction partly anticipated; the real test was whether the pivotal trial cleared its prespecified bar cleanly.

The pivotal trial delivered a decisive efficacy result. LUCIDITY met the FDA-agreed primary endpoint, reducing the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo through Week 16, with p=0.000003. 〔0〕 It also met all secondary endpoints across SMBG-measured Level 2 events, CGM-measured Level 2 events, and independently adjudicated Level 3 events. 〔1〕 That breadth is better than a narrow primary-endpoint win and supports an “above the bar” clinical read.

Safety did not introduce an obvious offsetting problem. Avexitide was generally well tolerated, most adverse events were mild to moderate, and the filing reports no serious adverse events related to treatment. 〔2〕 The most common events were diarrhea and injection-site reactions, with no observed change in body weight over the 16-week double-blind period. 〔3〕

The result materially advances the regulatory path, but it is not approval. Amylyx plans to submit an NDA by the end of 2026, with the 32-week open-label extension still ongoing. 〔4〕 The remaining uncertainty is therefore regulatory review, durability from the ongoing extension, and eventual commercial execution—not whether this trial met its stated efficacy objective. Net: a strong positive clinical readout versus the trial’s success bar, with the magnitude and clean secondary-endpoint profile supplying the surprise beyond the already expected catalyst.